The Australian technology funding picture in May 2026 is more uneven than the headline numbers suggest. Total venture investment is roughly in line with 2024, but the distribution has shifted in ways that matter for the longer-term health of the ecosystem.

AI-adjacent companies have captured a disproportionate share of seed and Series A funding. The Tech Council of Australia’s quarterly tracker shows AI startups taking 38% of seed deal flow in Q1 2026, up from 22% in 2023. Healthtech remains the second-strongest category, with several notable raises in the diagnostics and digital health space. Climate tech has held its share but the average deal size has compressed.

The story at later stages is less encouraging. Series C and growth-stage funding for Australian companies has continued the slow contraction visible since 2022, with a meaningful number of deals being completed at flat or down valuations relative to prior rounds. Founders raising Series C in 2026 are doing so against tighter terms, harder milestones, and less price tension between investors.

The capital sources

The composition of capital backing Australian technology companies has shifted. Local venture firms continue to lead seed and Series A. US-based growth funds remain active at later stages but are increasingly selective and increasingly inclined to require US incorporation or US revenue concentration as part of their commitment. Sovereign capital and superannuation participation in venture has grown, particularly through fund-of-fund arrangements, but remains a smaller share than the policy conversation has implied it should be.

The signal coming from the larger Australian super funds is that allocations to domestic venture will rise modestly over the next three years but not transformatively.

Where the gap is

The most consistent feedback from founders surveyed by industry bodies including the Tech Council of Australia and AIIA is that the Series B to Series C gap remains the structural weakness of the Australian funding ecosystem. The pool of investors writing 5M to 0M cheques into Australian companies is small. Companies in this stage often pursue US investors, which in turn pushes them toward US incorporation and US-centric go-to-market strategies. The downstream effect on the Australian sovereign tech capability is hard to measure but real.

The policy lens

Recent commentary from Treasury and from the Productivity Commission has begun to acknowledge the Series B to Series C gap as a policy issue. Proposed mechanisms include tax-advantaged co-investment structures, expanded R&D incentives for scale-up stage companies, and adjustments to early-stage venture capital limited partnership (ESVCLP) rules. The legislative timeline for any of these is uncertain.

The Australian Financial Review has reported that several major super funds are running internal reviews of their venture allocations, with findings due in the second half of 2026. Industry observers expect modest reallocation toward domestic technology, though not at a scale that closes the structural gap on its own.

The takeaway for the ecosystem

The Australian technology ecosystem in mid-2026 is healthier at early stages than late stages. The companies founded in 2023 and 2024 are well-funded and the talent pool supporting them is deep. The companies hitting Series B and C in 2026 are doing so in a harder market than their 2021 cohort experienced. The policy and capital responses to that imbalance will define the shape of the ecosystem entering 2028.